SRZN - Surrozen, Inc./DE
IEX Last Trade
14.1
-0.090 -0.638%
Share volume: 190
Last Updated: Fri 27 Dec 2024 08:23:37 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$14.19
-0.09
-0.63%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
20.85%
1 Month
44.62%
3 Months
44.20%
6 Months
48.69%
1 Year
73.48%
2 Year
85.56%
Key data
Stock price
$14.10
DAY RANGE
$14.18 - $15.19
52 WEEK RANGE
$6.55 - $16.19
52 WEEK CHANGE
$57.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Craig C. Parker
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Recent news